

=> fil reg

FILE 'REGISTRY' ENTERED AT 10:24:44 ON 19 JAN 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3
 DICTIONARY FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3


TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
 for more information. See STNote 27, Searching Properties in the CAS
 Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sta que 145
 L43 STR



Jan Delaval
 Reference Librarian
 Biotechnology & Chemical Library
 CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

NODE ATTRIBUTES:
 CONNECT IS M2 RC AT 11
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
 L45 1998 SEA FILE=REGISTRY CSS FUL L43

100.0% PROCESSED 14573 ITERATIONS
 SEARCH TIME: 00.00.01

1998 ANSWERS

=> d his

(FILE 'HOME' ENTERED AT 09:13:07 ON 19 JAN 2002)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 09:13:17 ON 19 JAN 2002

E WACHER V/AU
 L1 19 S E4-E6
 E BENET L/AU
 L2 420 S E3,E5-E7
 L3 911 S GALLIC ACID (L) ESTER?
 L4 1710 S (EPICATECHIN OR EPIGALLOCATECHIN OR GALLOCATECHIN) (L) GALLATE
 L5 9 S EPI() (CATECHIN OR GALLOCATECHIN OR GALLO()CATECHIN) (L) GALLATE

L6 4 S GALLO()CATECHIN(L)GALLATE
L7 5821 S TANNIC ACID
E TANNIN/CT
E E39+ALL
L8 138 S E9
L9 10753 S E8
L10 297 S E33-E38

FILE 'REGISTRY' ENTERED AT 09:19:10 ON 19 JAN 2002

L11 3 S 863-03-6 OR 989-51-5 OR 4233-96-9
E C22H18O10/MF
L12 67 S E3
L13 34 S E18
L14 101 S L12,L13
L15 40 S L14 AND 46.150.18/RID AND OC5-C6/ES AND 4/NR
L16 31 S L15 NOT IDS/CI
L17 29 S L16 AND 3 4 5 TRIHYDROXY
L18 19 S L17 AND 5 7 DIHYDROXY
L19 8 S L18 AND 3 4 DIHYDROXY

FILE 'REGISTRY' ENTERED AT 09:24:02 ON 19 JAN 2002

FILE 'REGISTRY' ENTERED AT 09:24:42 ON 19 JAN 2002

FILE 'REGISTRY' ENTERED AT 09:25:32 ON 19 JAN 2002

L20 7 S L19 NOT 213598-38-0
L21 11 S L18 NOT L19

FILE 'REGISTRY' ENTERED AT 09:26:48 ON 19 JAN 2002

L22 7 S L21 NOT (D OR T)/ELS
L23 14 S L11,L20,L22
SEL RN
L24 14 S E1-E14/CRN

FILE 'HCAPLUS' ENTERED AT 09:31:12 ON 19 JAN 2002

L25 1627 S L23
L26 9 S L24
L27 6 S L26 AND (1 OR 63 OR 26)/SC,SX
L28 3 S L26 NOT L27

FILE 'REGISTRY' ENTERED AT 09:33:09 ON 19 JAN 2002

L29 1 S 149-91-7

FILE 'HCAPLUS' ENTERED AT 09:33:14 ON 19 JAN 2002

L30 373 S L29/D
L31 163 S L29 (L) ESTER
L32 114 S L30 AND L31
L33 49 S L31 NOT L32
L34 1 S L33 AND 63/SC
L35 8544 S L32,L34,L25,L3-L8
L36 16809 S L9,L35
L37 16838 S L10,L36
L38 2 S L1,L2 AND L37
E ANMAX/PA,CS
L39 1 S E3-E6
E AVMAX/PA,CS
L40 12 S E3-E9
L41 2 S L37 AND L39,L40
L42 2 S L38,L41

FILE 'REGISTRY' ENTERED AT 09:37:55 ON 19 JAN 2002

L43 STR
L44 50 S L43 CSS
L45 1998 S L43 CSS FUL
SAV L45 KWON914/A
L46 1970 S L45 NOT L23,L24,L29

L47 STR L43
L48 8 S L47 CSS SAM SUB=L46
L49 160 S L47 CSS FUL SUB=L46
SAV L49 KWON914A/A
L50 83 S L49 AND 1/NC
L51 74 S L50 NOT IDS/CI
L52 77 S L49 NOT (L50 OR IDS/CI)
L53 63 S L52 NOT (MNS OR PMS)/CI
L54 4 S C6H8O6 AND L46
L55 1892 S L46 NOT L51,L54

FILE 'HCAPLUS' ENTERED AT 09:47:19 ON 19 JAN 2002

L56 2 S L54
L57 3093 S L51
L58 3 S L1,L2,L39,L40 AND L57
L59 3 S L42,L58

FILE 'REGISTRY' ENTERED AT 09:52:59 ON 19 JAN 2002

FILE 'HCAPLUS' ENTERED AT 09:53:34 ON 19 JAN 2002

SET SMARTSELECT ON
L60 SEL L59 1- RN : 58 TERMS
SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 09:53:34 ON 19 JAN 2002

L61 58 S L60
L62 3 S L61 AND L23,L24
L63 13 S L61 AND L57
L64 13 S L61 AND L46
L65 1 S L61 AND L29
L66 17 S L62-L65
L67 41 S L61 NOT L66
L68 40 S L67 NOT CYTOCHROME
L69 1 S L67 NOT L68

FILE 'HCAPLUS' ENTERED AT 10:10:00 ON 19 JAN 2002

L70 153676 S L68
L71 385 S L70 AND L37
L72 183 S L70 AND L57
L73 538 S L71,L72
L74 31335 S L69
L75 2 S L72,L73 AND L74
E DRUG BIOAVAILABILITY/CT
E E3+ALL
L76 12132 S E3
E E1+ALL
L77 154 S E1
E E2+ALL
E E6+ALL
L78 3184 S E5,E4+NT
E E9+ALL
L79 4162 S E2
E DRUG BIOAVAILABILITY/CT
E E3+ALL
E E7+ALL
L80 2154 S E5+NT
E E10+ALL
L81 19429 S L37,L57
L82 19 S L81 AND L76,L77
L83 7 SS L81 AND L78-L80
L84 25 S L82,L83
L85 16 S L84 NOT P/DT
SEL DN 1-4
L86 12 S L85 NOT E1-E4
L87 1 S L86 AND TANNIC ACID COMPLEX
L88 12 S L27,L56,L59,L87

L89 6 S L84 NOT L85,L88
 SEL DN 1 2 6
 L90 3 S L89 AND E5-E7
 L91 15 S L88,L90
 L92 15 S L91 AND L1-L10,L25-L28,L30-L42,L56-L59,L70-L91

FILE 'REGISTRY' ENTERED AT 10:24:44 ON 19 JAN 2002

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 10:24:56 ON 19 JAN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 19 Jan 2002 VOL 136 ISS 4

FILE LAST UPDATED: 17 Jan 2002 (20020117/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all tot 192

L92 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:923593 HCAPLUS

DN 136:42866

TI Bioavailable dosage form of isotretinoin

IN Pant, Abha; Bhatia, Inderdeep; Roy, Sunilendu Bhushan; Malik, Rajiv

PA Ranbaxy Laboratories Limited, India

SO PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-14

ICS A61K009-48; A61K031-20

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001095886	A1	20011220	WO 2001-IB581	20010409
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,			

VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI IN 2000-DE596 A 20000616

AB The present invention relates to a bioavailable pharmaceutical compn. of 13-cis-vitamin A acid (also known as 13-cis-retinoic acid and isotretinoin) and a process for prepg. the same. 13-Cis-vitamin A acid is a relatively water-insol. compd. that degrades when exposed to light and atm. oxygen. Due to its instability and relative insoly., the bioavailability of the drug after oral administration is difficult to achieve and has always been a challenge to a development pharmacist. It would therefore be desirable to provide a dosage form in which the drug is stable and predictably bioavailable. Thus, soft gelatin capsules contained isotretinoin 40, wax mixt. [hydrogenated soybean oil, white wax and hydrogenated vegetable oil (1:1.2:4.2)] 97.86, BHT 0.032, disodium diedetate 0.160, and soybean oil 181.0 mg.,.

ST isotretinoin bioavailable pharmaceutical; vitamin A acid bioavailable pharmaceutical

IT Antioxidants

Beeswax

Drug bioavailability

Drug delivery systems

Particle size distribution

Surface area

(bioavailable dosage form of isotretinoin)

IT Chelates

Cottonseed oil

Paraffin oils

Peanut oil

Polyoxyalkylenes, biological studies

Soybean oil

Tocopherols

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bioavailable dosage form of isotretinoin)

IT Drug delivery systems

(capsules; bioavailable dosage form of isotretinoin)

IT Soybean oil

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydrogenated; bioavailable dosage form of isotretinoin)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sesame; bioavailable dosage form of isotretinoin)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vegetable, hydrogenated; bioavailable dosage form of isotretinoin)

IT 4759-48-2, Isotretinoin

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bioavailable dosage form of isotretinoin)

IT 62-33-9, Calcium Disodium edetate 121-79-9, Propyl gallate

128-37-0, BHT, biological studies 137-66-6, Ascorbyl palmitate

139-33-3, Disodium edetate 25013-16-5, BHA 25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bioavailable dosage form of isotretinoin)

RE.CNT 3

RE

(1) La Roche, H; WO 0025772 A 2000 HCAPLUS

(2) Ortho Pharma Corp; EP 0184942 A 1986 HCAPLUS

(3) Straw, G; US 4808630 A 1989 HCAPLUS

L92 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:617777 HCAPLUS

DN 135:175411

TI Polyhydroxylated benzene-containing compounds for reducing food intake in

a subject
 IN Liao, Shutsung; Hiipakka, Richard A.; Kao, Yung-Hsi
 PA Arch Development Corporation, USA
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 1-11 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060319	A2	20010823	WO 2001-US4915	20010215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-183668	A2	20000218		
OS	MARPAT 135:175411				
AB	A method for reducing food intake in a subject and a method for reducing the levels of an endocrine in a subject. The methods include administering to the subject in need thereof an effective amt. of a polyhydroxylated benzene-contg. compds. Also disclosed is a liposomal prepn. which includes a liposome and a compd. entrapped therein.				
ST	benzene polyhydroxylated appetite depressant antiobesity agent				
IT	Blood (chem.; prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)				
IT	Phosphatidylcholines, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (complexes with polyhydroxylated benzenes; prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)				
IT	Drug delivery systems (liposomes; prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)				
IT	Antiobesity agents Appetite depressants Drug bioavailability Eosinophil Lymphocyte Monocyte Platelet (blood) (prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)				
IT	Hemoglobins RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)				
IT	Organ, animal Reproductive organ (wt. change; prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)				
IT	989-51-5	131580-20-6	355374-17-3	355374-18-4	355374-19-5
	355374-20-8 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)				
IT	9002-67-9, LH	9002-72-6, GH	67763-96-6, IGF-I	169494-85-3, Leptin	
	RL: BPR (Biological process); BIOL (Biological study); PROC (Process)				

(prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)

IT 610-02-6, 2,3,4-Trihydroxybenzoic acid 7699-31-2 32064-67-8, tert-Butylhydrazine
 RL: RCT (Reactant)
 (prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)

IT 355374-15-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)

IT 355374-14-0P 355374-16-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)

L92 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2002 ACS
 AN 2001:161509 HCAPLUS
 DN 134:202683
 TI Methods using a tea catechin for treating papilloma virus-associated hyperplasia
 IN Cheng, Shu Jun; Wang, De Chang; Hara, Yukihiro; Lee, Insu P.; Ahn, Woong Shick
 PA Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peop. Rep. China; Mitsui Norin Co., Ltd.
 SO U.S., 4 pp., Cont.-in-part of U.S. 5,968,973.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K031-35
 NCL 514456000
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6197808	B1	20010306	US 1999-418890	19991015
	US 5795911	A	19980818	US 1997-835920	19970410
	US 5968973	A	19991019	US 1998-56378	19980407
PRAI	US 1997-835920	A2	19970410		
	JP 1997-321195	A	19970915		
	US 1998-56378	A2	19980407		
	JP 1996-321195	A	19961118		
AB	A method for a treatment of hyperplasia caused by papilloma virus, such as Condyloma acuminata, comprises concomitantly topically and orally administering at least one tea catechin. Tea catechins do not involve the risk of side-effects and may be easily administered by the patients themselves.				
ST	tea catechin papillomavirus hyperplasia; Condyloma acuminata tea catechin				
IT	Reproductive tract (acuminate wart; tea catechin for treating papilloma virus-assocd. hyperplasia)				
IT	Drug delivery systems (capsules; tea catechin for treating papilloma virus-assocd. hyperplasia)				
IT	Antitumor agents (cervix carcinoma; tea catechin for treating papilloma virus-assocd. hyperplasia)				
IT	Uterus, neoplasm (cervix, carcinoma, inhibitors; tea catechin for treating papilloma virus-assocd. hyperplasia)				
IT	Uterus, neoplasm (cervix, carcinoma, intraepithelial; tea catechin for treating papilloma virus-assocd. hyperplasia)				
IT	Cell proliferation (inhibitors; tea catechin for treating papilloma virus-assocd.				

hyperplasia)
IT Drug delivery systems
(ointments, creams; tea catechin for treating papilloma virus-assocd.
hyperplasia)
IT Drug delivery systems
(ointments; tea catechin for treating papilloma virus-assocd.
hyperplasia)
IT Drug delivery systems
(oral; tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Drug delivery systems
(suppositories; tea catechin for treating papilloma virus-assocd.
hyperplasia)
IT Hyperplasia
Papillomavirus
Tea products
(tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Flavanols
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Drug delivery systems
(topical; tea catechin for treating papilloma virus-assocd.
hyperplasia)
IT Drug delivery systems
(vaginal; tea catechin for treating papilloma virus-assocd.
hyperplasia)
IT 970-74-1, (-)-Epigallocatechin 136511-29-0, Polyphenon 100
246537-81-5, Polyphenol E 328240-61-5
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(tea catechin for treating papilloma virus-assocd. hyperplasia)

RE.CNT 16

RE

- (1) Anon; DE 2206570 1972 HCAPLUS
- (2) Anon; JP 03141220 A 1991 HCAPLUS
- (3) Anon; EP 0417385 1991 HCAPLUS
- (4) Anon; DE 4211238 1993 HCAPLUS
- (5) Anon; GB 2293548 1996
- (6) Anon; WO 9628178 1996 HCAPLUS
- (7) Bombardelli; US 5605929 1997 HCAPLUS
- (8) Bombardelli; US 5648377 1997 HCAPLUS
- (9) Cheng; US 5795911 1998 HCAPLUS
- (10) Hirayama; US 5159069 1992 HCAPLUS
- (11) Hirose; Cancer Letters 1994, V83(1-2), P149 HCAPLUS
- (12) Mukhtar; Green Tea and Skin-Anticarcinogenic Effects 1994, V102(1), P3
MEDLINE
- (13) Shimamura; US 5135957 1992 HCAPLUS
- (14) Stich; Mutation Research 1990, V241(4), P387 HCAPLUS
- (15) Tempesta; US 5211944 1993 HCAPLUS
- (16) Williams; US 5576013 1996 HCAPLUS

L92 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:75302 HCAPLUS

DN 134:136674

TI Use of **gallic acid esters** to increase
bioavailability of orally administered pharmaceutical compounds

IN Wachter, Vincent J.; Benet, Leslie Z.

PA Anmax, Inc., USA

SO U.S., 12 pp., Cont.-in-part of U.S. 5,962,522.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-235

ICS A61K031-353

NCL 514544000

CC 63-5 (Pharmaceuticals)

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6180666	B1	20010130	US 1999-264215	19990305
	US 5962522	A	19991005	US 1997-926309	19970905
	WO 2000051643	A1	20000908	WO 2000-US5524	20000301
	W: AU, CA, JP, NZ, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1159007	A1	20011205	EP 2000-912149	20000301
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-926309	A2	19970905		
	US 1999-264215	A	19990305		
	WO 2000-US5524	W	20000301		
OS	MARPAT 134:136674				
AB	A method is disclosed for increasing bioavailability of an orally administered pharmaceutical compd. comprising orally coadministering the pharmaceutical compd. to a mammal in need of treatment with the compd. and a gallic acid ester . Preferred gallic acid esters of the invention include octyl gallate, Pr gallate, lauryl gallate, and Me gallate. Improved formulations of pharmaceutical compds. include the gallic acid ester to enhance the bioavailability of the active ingredient of the pharmaceutical compd. Octyl gallate at 100 .mu.M decreased the relative nifedipine oxidn. of CYP3A metab. in human liver microsome from 100 to 1.1.				
ST	gallic ester bioavailability oral pharmaceutical				
IT	Rauvolfia (alkaloids; use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compds.)				
IT	Antibiotics (anthracycline; use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compds.)				
IT	Estrogens RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antiestrogens; use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compds.)				
IT	Peptides, biological studies RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cyclic; use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compds.)				
IT	Natural products, pharmaceutical RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (digitalis; use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compds.)				
IT	Alkaloids, biological studies RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ergot; use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compds.)				
IT	Amines, biological studies RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (phenylalkyl; use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compds.)				
IT	Drug bioavailability (use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compds.)				
IT	Anilides				

Cannabinoids
 Glycosides
 Hydrocarbons, biological studies
 Macrolides
 Opioids
 Retinoids
 Steroids, biological studies
 Sulfones
 Sulfonylureas

RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of **gallic acid esters** to increase
 bioavailability of orally administered pharmaceutical compds.)

IT Alkaloids, biological studies

RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vinca; use of **gallic acid esters** to
 increase bioavailability of orally administered pharmaceutical compds.)

IT 55-86-7, Nitrogen mustard, 64-86-8, Colchicine,
 69-72-7, biological studies 91-20-3, Naphthalene,
 biological studies 91-22-5D, Quinoline, derivs. 92-84-2D
 , Phenothiazine, derivs. 103-84-4, Acetanilide 106-51-4D
 , Quinone, derivs. 110-85-0D, Piperazine, derivs.
 110-86-1D, Pyridine, derivs. 110-89-4, Piperidine,
 biological studies 119-65-3, Isoquinoline 123-75-1D,
 Pyrrolidine, derivs. 253-82-7D, Quinazoline, derivs.
 256-96-2, 5H-Dibenz[b,f]azepine 271-89-6, Benzofuran
 288-32-4, Imidazole,, biological studies 288-42-6D,
 Oxazole, derivs. 289-95-2D, Pyrimidine, derivs. 478-88-6
 , Ergoline 529-17-9, Tropane 588-59-0, Stilbene
 4375-07-9, Epipodophyllotoxin 11084-05-2D, Oxazine,
 derivs. 11111-12-9, Cephalosporin 27254-80-4,
 Aminoacridine 27790-75-6, Dihydropyridine, 28261-54-3,
 Pyrrolidinone 28261-54-3D, Pyrrolidinone, derivs.
 31135-62-3, Aminoquinoline 33069-62-4, Paclitaxel
 37306-44-8D, Triazole, derivs.

RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of **gallic acid esters** to increase
 bioavailability of orally administered pharmaceutical compds.)

IT 99-24-1, Methyl gallate. 121-79-9, Propyl gallate
 149-91-7D, Gallic acid, esters
 1034-01-1, Octyl gallate 1166-52-5, Lauryl gallate
 15674-66-5 36362-22-8 291506-30-4
 291506-31-5 291506-33-7 291506-34-8
 291506-35-9 291506-36-0

RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological
 study); PROC (Process); USES (Uses)
 (use of **gallic acid esters** to increase
 bioavailability of orally administered pharmaceutical compds.)

RE.CNT 30

RE

- (1) Anon; GB 997914 1965 HCAPLUS
- (2) Anon; EP 0184942 A2 1986 HCAPLUS
- (3) Anon; EP 0295941 B1 1988 HCAPLUS
- (4) Anon; EP 0314384 A2 1989 HCAPLUS
- (5) Anon; WO 9520980 1995 HCAPLUS
- (6) Anon; WO 9601128 1996 HCAPLUS
- (7) Anon; WO 9640192 1996 HCAPLUS
- (8) Apostolides, Z; Mutation Research 1997, V389(2-3), P167 MEDLINE
- (9) Baer-Dubowska, W; Xenobiotica 1998, V28(8), P735 HCAPLUS
- (10) Bamforth, K; Biochem Pharmacol 1993, V46(10), P1713 HCAPLUS
- (11) Benet; US 5567592 1996 HCAPLUS
- (12) Benet; US 5665386 1997 HCAPLUS
- (13) Bernard; US 3282789 1966 HCAPLUS
- (14) Bonkovsky; Gastroenterology 1985, V88, P458 HCAPLUS

- (15) Bourrie, M; J Pharmacol Exp Ther 1996, V277(1), P321 HCAPLUS
 (16) Bradford, M; Anal Biochem 1976, V72, P248 HCAPLUS
 (17) Burke, M; Biochem Pharmacol 1985, V34(18), P337
 (18) Clarke, S; Xenobiotica 1994, V24, P517 HCAPLUS
 (19) Fabre, G; Drug Metab Dispos 1993, V21(6), P978 HCAPLUS
 (20) Fasco; Mol Pharmacol 1993, V43, P226 HCAPLUS
 (21) Gallo-Torres; US 4310543 1982 HCAPLUS
 (22) Gonzalez, F; DNA 1988, V7(2), P79 HCAPLUS
 (23) Greenblatt, D; J Clin Pharmacol 1993, V33, P650 MEDLINE
 (24) Kaminsky; Toxicology 1992, V21(6), P407 HCAPLUS
 (25) Kedderis, G; J Biol Chem 1980, V255(21), P10174 HCAPLUS
 (26) Kedderis, G; Microsomes, Drug Oxid, Chem Carcinog, Int Symp Microsomes
 Drug Oxid 1980, V1, P351 HCAPLUS
 (27) Kelleher, J; Biochem Soc Transact 1976, V4, P292 HCAPLUS
 (28) Kelleher, J; J Ind Med Res 1976, V4(suppl 4), P138
 (29) Mulligan; US 5156842 1992 HCAPLUS
 (30) Salantinjants; US 4716173 1987 HCAPLUS

L92 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:628027 HCAPLUS

DN 133:227794

TI Use of **gallic acid esters** to increase
 bioavailability of orally administered pharmaceutical compounds

IN Wachter, Vincent J.; Benet, Leslie Z.

PA Avmax, Inc., USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K047-14

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000051643	A1	20000908	WO 2000-US5524	20000301
	W: AU, CA, JP, NZ, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6180666	B1	20010130	US 1999-264215	19990305
	EP 1159007	A1	20011205	EP 2000-912149	20000301
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1999-264215	A	19990305		
	US 1997-926309	A2	19970905		
	WO 2000-US5524	W	20000301		

OS MARPAT 133:227794

AB A method for increasing bioavailability of an orally administered pharmaceutical compd. comprises orally coadministering the pharmaceutical compd. to a mammal in need of treatment with the compd. and a **gallic acid ester**. Preferred **gallic acid esters** of the invention include octyl gallate, Pr gallate, lauryl gallate, and Me gallate. Improved formulations of pharmaceutical compds. include the **gallic acid ester** to enhance the bioavailability of the active ingredient of the pharmaceutical compd. Examples were given for inhibition of drug degrdn. by **gallic acid esters** and inhibition of nifedipine degrdn. by heterocyclic **gallic acid esters** such as (-)-**epicatechin gallate**.

ST gallate ester oral drug bioavailability

IT Peptides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclic; **gallic acid esters** to increase
 bioavailability of oral pharmaceuticals)

IT Alkaloids, biological studies

Cannabinoids
Glycosides
Retinoids
Steroids, biological studies
Sulfonylureas

Tannins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**gallic acid esters** to increase
bioavailability of oral pharmaceuticals)

IT Chloramines

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrogen mustards; **gallic acid esters** to
increase bioavailability of oral pharmaceuticals)

IT **Drug bioavailability**

(oral; **gallic acid esters** to increase
bioavailability of oral pharmaceuticals)

IT 99-24-1, Methyl gallate 1034-01-1, Octyl gallate
1166-52-5, Lauryl gallate

RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological
study); PROC (Process); USES (Uses)
(**gallic acid esters** to increase
bioavailability of oral pharmaceuticals)

IT 64-86-8, Colchicine 103-84-4, Acetanilide
989-51-5, (-)-Epigallocatechin gallate
1257-08-5 4233-96-9, (-)-Gallocatechin
gallate 11111-12-9, Cephalosporin 12794-10-4D,
Benzodiazepine, derivs. 15674-66-5 36362-22-8
291506-30-4 291506-31-5 291506-32-6
291506-33-7 291506-34-8 291506-35-9
291506-36-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**gallic acid esters** to increase
bioavailability of oral pharmaceuticals)

RE.CNT 9

- RE
- (1) Avmax Inc; WO 9640192 A 1996 HCAPLUS
 - (2) Avmax Inc; WO 9911290 A 1999 HCAPLUS
 - (3) Baer-Dubowska, W; XENOBIOTICA 1998, V28(8), P735 HCAPLUS
 - (4) Neisler Laboratories Inc; GB 997914 A 1965 HCAPLUS
 - (5) Neisler Laboratories Inc; US 3282789 A 1966 HCAPLUS
 - (6) Obermeier, M; XENOBIOTICA 1995, V25(6), P575 HCAPLUS
 - (7) Salatinjants Aida; US 4716173 A 1987 HCAPLUS
 - (8) Schering Ag; WO 9601128 A 1996 HCAPLUS
 - (9) Wachter, V; JOURNAL OF PHARMACEUTICAL SCIENCES 1998, V87(11), P1322 HCAPLUS

L92 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:184156 HCAPLUS

DN 130:227711

TI Use of propyl gallate to increase bioavailability of orally administered
pharmaceutical compounds

IN Wachter, Vincent J.; Benet, Leslie Z.

PA Avmax, Inc., USA

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K047-14

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911290	A1	19990311	WO 1998-US18444	19980903
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE				

US 5962522 A 19991005 US 1997-926309 19970905
 EP 1009437 A1 20000621 EP 1998-946843 19980903
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 JP 2001514234 T2 20010911 JP 2000-508391 19980903
 PRAI US 1997-926309 A 19970905
 WO 1998-US18444 W 19980903
 AB A method for increasing bioavailability of an orally administered
 pharmaceutical compd. comprises orally administering the pharmaceutical
 compd. to a mammal in need of treatment with the compd. concurrently with
 Pr gallate. Improved formulations of pharmaceutical compds. include Pr
 gallate to enhance the bioavailability of the active ingredient of the
 pharmaceutical compd. Pr gallate at 100 .mu.M decreased CYP3A-mediated
 metab. of amiodarone in human liver microsomes to 17% of the controls.
 ST propyl gallate bioavailability oral pharmaceutical amiodarone
 IT Natural products (pharmaceutical)
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (digitalis; use of Pr gallate to increase bioavailability of orally
 administered pharmaceutical compds.)
 IT Alkaloids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ergot; use of Pr gallate to increase bioavailability of orally
 administered pharmaceutical compds.)
 IT Alkaloids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (of Rauwolfia; use of Pr gallate to increase bioavailability of orally
 administered pharmaceutical compds.)
 IT Amines, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phenylalkyl; use of Pr gallate to increase bioavailability of orally
 administered pharmaceutical compds.)
 IT Antibiotics
Drug bioavailability
 Drug delivery systems
 (use of Pr gallate to increase bioavailability of orally administered
 pharmaceutical compds.)
 IT Anilides
 Anthracyclines
 Antiestrogens
 Cannabinoids
 Cyclic peptides
 Macrolides
 Opioids
 Polycyclic aromatic hydrocarbons
 Retinoids
 Steroids, biological studies
 Sulfones
 Sulfonylureas
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of Pr gallate to increase bioavailability of orally administered
 pharmaceutical compds.)
 IT Alkaloids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vinca; use of Pr gallate to increase bioavailability of orally
 administered pharmaceutical compds.)
 IT 121-79-9, Propyl gallate
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of Pr gallate to increase bioavailability of orally administered
 pharmaceutical compds.)
 IT 9035-51-2D, Cytochrome p450, inhibitors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (use of Pr gallate to increase bioavailability of orally administered
 pharmaceutical compds.)
 IT 55-86-7, Nitrogen mustard 64-86-8, Colchicine
 69-72-7D, derivs. 91-20-3, Naphthalene, biological

studies 91-22-5, Quinoline, biological studies 92-84-2
 , Phenothiazine 103-84-4, Acetanilide 106-51-4,
 Quinone, biological studies 110-85-0, Piperazine, biological
 studies 110-86-1, Pyridine, biological studies 110-89-4
 , Piperidine, biological studies 119-65-3, Isoquinoline
 123-75-1, Pyrrolidine, biological studies 253-82-7,
 Quinazoline 256-96-2, 5H-Dibenz[b,f]azepine 264-54-0,
 1H-1-Benzazepine 271-89-6, Benzofuran 288-32-4,
 Imidazole, biological studies 288-42-6, Oxazole 289-95-2
 , Pyrimidine 290-04-0, 2H-1,3-Oxazine 478-88-6,
 Ergoline 529-17-9, Tropane 588-59-0, Stilbene
 1951-25-3, Amiodarone 4096-20-2 4375-07-9,
 Epipodophyllotoxin 4471-17-4D, Benzhydryl, compds.
 11111-12-9, Cephalosporin 12794-10-4, Benzodiazepine
 21829-25-4, Nifedipine 27254-80-4, Aminoacridine
 27790-75-6, Dihydropyridine 28261-54-3, Pyrrolidinone
 31135-62-3, Aminoquinoline 33069-62-4, Taxol
 36505-84-7, Buspirone 37306-44-8, Triazole
 37342-64-6, Pyridone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of Pr gallate to increase bioavailability of orally administered
 pharmaceutical compds.)

RE.CNT 6

RE

- (1) Kedderis, G; JOURNAL OF BIOLOGICAL CHEMISTRY 1980, V255(21), P10174 HCAPLUS
- (2) Kedderis, G; MICROSOMES, DRUG OXID, CHEM CARCINOGEN, INT SYMP MICROSOMES
 DRUG OXID, 4TH 1980, V1, P351 HCAPLUS
- (3) Leslie, B; US 5567592 A 1996 HCAPLUS
- (4) Ortho Pharma Corp; EP 0184942 A 1986 HCAPLUS
- (5) Raychem Corp; EP 0314384 A 1989 HCAPLUS
- (6) Yang, C; BIOCHEM PHARMACOL 1974, V23(22), P3129 HCAPLUS

L92 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:95043 HCAPLUS

DN 128:221622

TI Enhancement of antitumor efficacy with tea catechins and/or theaflavins
 and antitumor agents with enhanced efficacy

IN Chen, Shu Jun; Wong, De Chang; Zen, Yon Su; Nishino, Sukeyoku; Hara,
 Yukihiro

PA Mitsui Norin Co., Ltd., Japan; Cancer Institute of Medical Biotechnology,
 Chinese Academy of Medical Science; Institute of Medical Biotechnology,
 Chinese Academy of Medical Science

SO Jpn. Kokai Tokkyo Koho, 1996, 5, pp. 5, 1996

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K031-35

ICS A61K031-35; A61K031-505; A61K031-70; A61K045-00; A61K035-78;
 C07D311-62

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10036260	A2	19980210	JP 1996-206361	19960718
	EP 819433	A2	19980121	EP 1996-120973	19961228
	EP 819433	A3	19990512		
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	AU 9676515	A1	19980129	AU 1996-76515	19961230
	AU 690863	B2	19980430		
	CA 2195606	AA	19980119	CA 1997-2195606	19970121
	CN 1171238	A	19980128	CN 1997-102362	19970130
	US 5804567	A	19980908	US 1997-919716	19970827
PRAI	JP 1996-206361		19960718		
	US 1996-770553		19961223		

AB Efficacy of antitumor agents are enhanced upon adding tea catechins and/or

- teaflavins. Also claimed are antitumor agents whose efficacy is enhanced as described above. Combined administration of cytarabine and **epigallocatechin gallate** to mice bearing leukemia L 1210 significantly prolonged the survival rate after 60 days.
- ST antitumor efficacy enhancement tea catechin teaflavin; cytarabine antitumor efficacy enhancement **epigallocatechin gallate**; methotrexate antitumor efficacy enhancement **epigallocatechin gallate**
- IT Nutrients
(anti-; enhancement of antitumor activity with tea catechins and/or theaflavins)
- IT Antitumor agents
Synergistic drug interactions
(enhancement of antitumor activity with tea catechins and/or theaflavins)
- IT Flavanols
Polyphenols (nonpolymeric)
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enhancement of antitumor activity with tea catechins and/or theaflavins)
- IT **863-03-6, Epicatechin gallate** 970-74-1, **Epigallocatechin 989-51-5, Epigallocatechin gallate** 33377-72-9, **Theaflavin digallate 204137-25-7 204137-26-8**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enhancement of antitumor activity with tea catechins and/or theaflavins)
- L92 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2002 ACS
- AN 1997:101120 HCAPLUS
- DN 126:242804
- TI Hydrogels for ocular delivery of pilocarpine. Preliminary evaluation in rabbits of the influence of viscosity and of drug solubility
- AU Burgalassi, Susi; Chetoni, Patrizia; Saettone, M. Fabrizio
- CS Dep. Pharmaceutical Technol. Biopharmacy, Univ. Pisa, Pisa, Italy
- SO Eur. J. Pharm. Biopharm. (1996), 42(6), 385-392
CODEN: EJPBEL; ISSN: 0939-6411
- PB Wissenschaftliche Verlagsgesellschaft
- DT Journal
- LA English
- CC 63-6 (Pharmaceuticals)
- AB Two distinct approaches, mucoadhesion and reduced drug soly., were applied to develop improved hydrogels for delivery of pilocarpine. Xyloglucan gum, xanthan gum, pectin, hydroxypropyl Me cellulose, and polyvinyl alc. were used at various concns. to prep. 2 series of iso-viscous hydrogels (series 1 and 2) characterized by apparent (pseudoplastic) viscosities of 0.03 and 6.00 Pas at a shear rate of 1.0 s⁻¹. The more viscous gels (series 2), tested in vitro for adhesion on hog gastric mucin, showed high work of adhesion values. Both series contained pilocarpine as the nitrate (2.0% wt./wt.), while a 3rd hydrogel series, having the same polymer compn. and viscosity as series 2, contained pilocarpine as a poorly sol. **tannic acid complex**. All hydrogels were tested in vivo on rabbits for pilocarpine release to the tear fluid and for miotic effect. The trans-corneal delivery of the drug was also tested. The overall biol. activity increased in the order series 1 < series 2 < series 3. Hence, the use of a sparingly sol. pilocarpine complex in combination with selected viscous, mucoadhesive hydrogels can result in prolonged activity and increased bioavailability.
- ST pilocarpine ophthalmic delivery hydrogel adhesion miosis; eye drop pilocarpine hydrogel adhesion miosis
- IT **Tannins**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(complexes, with pilocarpine; hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)

- IT Mucins
RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(gastric; hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
- IT Adhesion (physical)
Conjunctiva
Drug bioavailability
Eye
Hydrogels (drug delivery systems)
Miosis
Ophthalmic drug delivery systems
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
- IT 54-71-7, Pilocarpine hydrochloride
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
- IT 92-13-7D, Pilocarpine, **tannic acid complexes**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
- IT 148-72-1, Pilocarpine nitrate
RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
- IT 9000-69-5, Pectin 9002-89-5, Polyviol W28/20 9004-65-3, Methocel E15LV 11138-66-2, Keltrol TF 37294-28-3, Xyloglucan 76050-42-5, Carbopol 940
RL: MOA (Modifier or additive use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)

L92 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:444021 HCAPLUS

DN 125:85253

TI Absorbents for oxygen as preservatives in beverages

IN Takai, Yuka

PA Toppan Printing Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM B01J020-22

ICS A23L003-3436; B01D053-14

CC 17-13 (Food and Feed Chemistry)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08117592	A2	19960514	JP 1994-262690	19941026
AB	An oxygen absorbent contains ascorbic acid or its salt, and gallic acid (or benzoic acid, m-hydroxybenzoic acid, p-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid, p-nitrobenzoic acid, terephthalic acid) at pH 4-5, and is used in beverages like fruit juice and sake.				
ST	oxygen absorbent ascorbate benzoate gallate beverage				
IT	Beverages				
	(absorbents for oxygen in beverages)				
IT	Absorbents				
	(for oxygen in beverages)				
IT	7782-44-7, Oxygen, biological studies			87491-34-7	115973-42-7
	178858-62-3	178858-64-5	178858-66-7	178858-68-9	178858-70-3
	178858-73-6	178858-76-9	178858-78-1	178858-81-6	178858-83-8
	178858-85-0	178858-86-1	178858-87-2		

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (absorbents for oxygen in beverages)

L92 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 1993:538313 HCAPLUS

DN 119:138313

TI Active oxygen free radical removers

IN Kogasaki, Keiichi

PA Sukai Fuudo Kk, Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K035-78

ICS A23L001-30; A61K035-78

CC 18-7 (Animal Nutrition)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05139987	A2	19930608	JP 1991-297455	19911113
	JP 07112979	B4	19951206		
AB	Active O free radical removers contain epigallocatechin gallate -contg. green tea leaf exts. and chlorogenic acid-contg. sunflower seed exts. The removers are useful for treatment of inflammation, stroke, arteriosclerosis, cancer, aging, etc. Rats were fed a diet contg. green tea leaf ext. and sunflower seed ext. for 20 days to show remarkable decrease in urinary methylguanidine. Beverages contg. green tea leaf ext. and sunflower seed ext. were manufd.				
ST	epigallocatechin chlorogenate active oxygen remover; tea sunflower active oxygen remover; anticancer antiinflammatory epigallocatechin chlorogenate; cardiovascular agent epigallocatechin chlorogenate				
IT	Beverages Cardiovascular agents Food Inflammation inhibitors Neoplasm inhibitors (epigallocatechin gallate and chlorogenic acid as active oxygen removers for)				
IT	Reactive oxygen species RL: BIOL (Biological study) (removers for, epigallocatechin gallate and chlorogenic acid as)				
IT	Sunflower (seed, exts., active oxygen removers contg. green tea leaf ext. and)				
IT	Tea products (leaves, exts., active oxygen removers contg. sunflower seed ext. and)				
IT	149691-10-1 RL: BIOL (Biological study) (active oxygen removers contg., of green tea leaf and sunflower seed)				
IT	7782-44-7D, Oxygen, reactive species RL: BIOL (Biological study) (removers for, epigallocatechin gallate and chlorogenic acid as)				

L92 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 1993:139282 HCAPLUS

DN 118:139282

TI Inhibitory effect of **tannic acid** sulfate and related sulfates on infectivity, cytopathic effect, and giant cell formation of human immunodeficiency virus

AU Mizuno, Takashi; Uchino, Keiichi; Toukairin, Toshikatsu; Tanabe, Akiko; Nakashima, Hideki; Yamamoto, Naoki; Ogawara, Hiroshi

CS Cent. Lab., Nippon Flour Mills Co., Ltd., Atsugi, 243, Japan

SO Planta Med. (1992), 58(6), 535-9


CODEN: PLMEAA; ISSN: 0032-0943

DT Journal
 LA English
 CC 1-5 (Pharmacology)
 AB The acquired immune deficiency syndrome (AIDS) is thought to result from infection of T cells by a pathogenic human retrovirus, human immunodeficiency virus [HIV (HTLV-III/LAV)]. In this report, the authors synthesized sulfated plant polyphenols such as **tannic acid** sulfate, rutin sulfate, ellagic acid sulfate, (-)-**epicatechin** sulfate, and (-)-**epigallocatechin** 3-**gallate** sulfate, and examd. the in vitro inhibitory effect on HIV infection using human T-cell lymphotropic virus type-I-carrying MT-4 cells, which are extremely susceptible to HIV infection. Of the compds. tested, **tannic acid** sulfate was the most effective and had low cytotoxicity. **Tannic acid** sulfate completely inhibited the cytopathic effect of HIV and the HIV-specific antigen expression in MT-4 cells at the concn. of 6 .mu.g/mL. In addn., this sulfate inhibited giant cell formation in coculture at the concn. of 5 .mu.g/mL.

ST polyphenol sulfate human immunodeficiency virus; **tannic acid** sulfate human immunodeficiency virus
 IT Virucides and Virustats
 (**tannic acid** sulfate and related sulfates as, against HIV)
 IT Acquired immune deficiency syndrome
 (**tannic acid** sulfate and related sulfates for treatment of)
 IT Virus, animal
 (human immunodeficiency, **tannic acid** sulfate and related sulfates activity against)
 IT **Tannins**
 RL: BIOL (Biological study)
 (sulfates, HIV infectivity and cytopathic effect and giant cell formation inhibition by)
 IT 77271-53-5, Rutin sulfate 114845-21-5 139202-72-5 **146479-42-7**
 RL: BIOL (Biological study)
 (HIV infectivity and cytopathic effect and giant cell formation inhibition by)
 IT 27073-41-2
 RL: BIOL (Biological study)
 (sulfated, HIV infectivity and cytopathic effect and giant cell formation inhibition by)

L92 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2002 ACS
 AN 1993:116759 HCAPLUS
 DN 118:116759
 TI gallic acids as collagenase inhibitors for treatment of periodontosis
 IN Inoue, Shintaro; Ota, Hideko; Tonomura, Mikio; Maeda, Masao; Iguchi, Keiji
 PA Kanebo, Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 IC ICM A61K031-19
 ICS A23G003-00; A23G003-30; A61K007-24; A61K031-235; A61K031-375;
 C12N009-99
 CC 1-9 (Pharmacology)
 Section cross-reference(s): 62
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04290819	A2	19921015	JP 1991-76710	19910315
OS	MARPAT 118:116759				
GI					



- AB The collagenase inhibitors gallic acids I (X = H, salt residue, C1-4 alkyl) or their salts are effective in treating periodontosis. Gallic acid, Me gallate, and Et gallate at 1.70, 1.86, and 2.00 .mu.g/mL, resp. inhibited human collagenase by 50%, vs. 0% for isoamyl gallate (0.1 mg/mL). Combination of gallates with ascorbic acid or erythorbic acid showed synergistic effect. Dentifrices and mouthwashes contg. I were formulated.
- ST gallate collagenase inhibitor periodontosis treatment; dentifrice gallate collagenase inhibitor; synergism collagenase inhibitor ascorbate erythorbate
- IT Dentifrices
Mouthwashes
(contg. gallates, for periodontosis treatment)
- IT Periodontium
(disease, periodontosis, treatment of, gallates as collagenase inhibitors for)
- IT 9001-12-1, Collagenase
RL: BIOL (Biological study)
(inhibitors for, gallates as, for periodontosis treatment)
- IT 50-81-7, Ascorbic acid, biological studies 89-65-6, Erythorbic acid
RL: BIOL (Biological study)
(periodontosis treatment by collagenase inhibitor and)
- IT 99-24-1, Methyl gallate 121-79-9, Propyl gallate
149-91-7, Gallic acid, biological studies 831-61-8, Ethyl gallate 1083-41-6, Butyl gallate 3856-05-1, Isobutyl gallate 87491-34-7 146161-88-8 146161-89-9 146161-90-2
RL: BIOL (Biological study)
(periodontosis treatment by, collagenase inhibition in relation to)

L92 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 1991:648130 HCAPLUS

DN 115:248130

TI Flavonoids for protection of cells against chemically active species of oxygen, their extraction from plants, and their use in cosmetics

IN Park, Soo Nam; Boo, Yong Chool

PA Pacific Chemical Co., Ltd., S. Korea

SO Fr. Demande, 17 pp.

CODEN: FRXXBL

DT Patent

LA French

IC ICM A61K035-78

ICS A61K031-35

CC 1-12 (Pharmacology)

Section cross-reference(s): 11, 62, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2651132	A1	19910301	FR 1990-935	19900126
	FR 2651132	B1	19930108		
	KR 9707186	B1	19970507	KR 1989-12435	19890820
	JP 03093782	A2	19910418	JP 1990-16320	19900129
	JP 07103025	B4	19951108		
PRAI	KR 1989-12435	A	19890830		
	KR 1989-12492	A	19890831		

- KR 1989-12493 A 19890831
- AB Flavonoids are extd. from plants for use as agents to protect cells against chem. active species of O. Cosmetic compns. contain these protective agents. (-)-**Epigallocatechin gallate** (I) was prepd. by extn. from dry leaves of *Camellia sinensis* L. Galangin was extd. from dry *Alpinia officinarum* Hance roots. In a photohemolysis assay, a 1:1 mixt. of I and galangin gave a half-hemolysis time of >2000 min (compared with 32 min for controls). Each, alone, gave values of 400 and 1800, resp.
- ST cell protection oxygen flavonoid plant; cosmetic flavonoid cell protection oxygen; **epigallocatechin gallate** *Camellia* cell oxygen; galangin *Alpinia* cell protection oxygen
- IT *Scutellaria baicalensis*
(baicalein of root of, for protection of cells against chem. active forms of oxygen)
- IT Flavonoids
RL: BIOL (Biological study)
(cells protection with, from chem. active forms of oxygen)
- IT Cosmetics
(contg. plant flavonoids for protection of cells against chem. active forms of oxygen)
- IT Tea (*Camellia sinensis*)
(**epigallocatechin gallate** of, for protection of cells against chem. active forms of oxygen)
- IT Leaf
(**epigallocatechin gallate** of, of *Camellia sinensis*, for protection of cells against chem. active forms of oxygen)
- IT *Citrus tangerina*
Tanaka
(flavonoid of fruit rind of, for protection of cells against chem. active species of oxygen)
- IT *Acacia catechu*
Ginkgo biloba
(flavonoid of leaves of, for protection of cells against chem. active species of oxygen)
- IT *Alpinia officinarum*
(galangin of root of, for protection of cells against chem. active forms of oxygen)
- IT Root
(galangin of, of *Alpinia officinarum*, for protection of cells against chem. active forms of oxygen)
- IT Cell
(protection of, against chem. active forms of oxygen, plant flavonoids for)
- IT Plant tissue
(rind, flavonoid of, of *Citrus tangerina*, for protection of cells against chem. active species of oxygen)
- IT 491-67-8, Baicalein 548-83-4, Galangin **989-51-5** 137425-06-0
137425-07-1
RL: BIOL (Biological study)
(cells protection with, from chem. active forms of oxygen)
- IT 117-39-5, Quercetin 153-18-4, Rutin 154-23-4, (+)-Catechin 480-16-0, Morin 480-18-2, Taxifolin 480-20-6, Aromadendrin 480-40-0, Chrysin 480-44-4, Acacetin 490-46-0, (-)-Epicatechin 520-18-3, Kaempferol 520-36-5, Apigenin 525-82-6, Flavone 528-48-3, Fisetin 529-44-2, Myricetin 577-85-5, 3-Hydroxyflavone 604-59-1, 7,8-Benzoflavone 4382-33-6, Dihydrorobinetin 21967-41-9, Baicalin 22888-70-6, Silybin
RL: BIOL (Biological study)
(chem. active oxygen species effect on cells response to)
- IT 7782-44-7D, Oxygen, chem.-active forms
RL: BIOL (Biological study)
(flavonoids from plants for protection of cells against)

- TI Polyphenol interactions. Part 4. Model studies with caffeine and cyclodextrins
- AU Cai, Ya; Gaffney, Simon H.; Lilley, Terence H.; Magnolato, Daniele; Martin, Russell; Spencer, Catriona M.; Haslam, Edwin
- CS Dep. Chem., Univ. Sheffield, Sheffield, S3 7HF, UK
- SO J. Chem. Soc., Perkin Trans. 2 (1990), (12), 2197-209
CODEN: JCPKBH; ISSN: 0300-9580
- DT Journal
- LA English
- CC 26-4 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 22, 33
- AB The reversible complexation of phenols and natural polyphenols with caffeine, related heterocycles, and .alpha.- and .beta.-cyclodextrin is examd. Assocn. consts. (K) for 1:1 complexes between caffeine and natural polyphenols are detd. (15-138 dm³ mol⁻¹). Among galloyl esters there is a dependence of strong binding on mol. size, conformational flexibility, and the free galloyl ester group content of the polyphenol. With phenolic flavan-3-ols, assocn. is enhanced by galloylation at C-3. The extent of pptn. of polyphenols by caffeine is related to K, the mol. size of the polyphenol, and the initial concn. of both substrates. Compared with that of the natural galloyl esters (K 76-340 dm³ mol⁻¹), the binding of phenolic flavan-3-ols to .beta.-cyclodextrin is strong (K 210-6231 dm³ mol⁻¹). Models are proposed for encapsulation within the cyclodextrin cavity. Hydrophobic effects and hydrogen bonding are discussed.
- ST complexation polyphenol caffeine cyclodextrin; assocn phenol caffeine cyclodextrin
- IT Overhauser effect
(for polyphenol-cyclodextrin complexes)
- IT Hydrogen bond
Molecular association
(of phenols and polyphenols with caffeine and cyclodextrins)
- IT Nuclear magnetic resonance
(of phenols and polyphenols, effect of cyclodextrin on)
- IT Heat of hydrogen bonding
(of polyphenols with caffeine)
- IT 154-23-4, (+)-Catechin 490-46-0, (-)-Epicatechin 970-73-0,
(+)-Gallocatechin 970-74-1, (-)-Epigallocatechin 989-51-5
24808-04-6 25615-05-8, (+)-Catechin 3-gallate
RL: PRP (Properties)
(NMR of, effect of cyclodextrin on)
- IT 89-86-1, 2,4-Dihydroxybenzoic acid 99-24-1, Methyl gallate
99-50-3, 3,4-Dihydroxybenzoic acid 99-96-7, properties 100-02-7,
p-Nitrophenol, properties 108-46-3, 1,3-Benzenediol, properties
108-73-6, 1,3,5-Benzenetriol 120-80-9, 1,2-Benzenediol, properties
121-79-9, Propyl gallate 123-31-9, 1,4-Benzenediol, properties
149-91-7, 3,4,5-Trihydroxybenzoic acid, properties 497-76-7
831-61-8, Ethyl gallate 2150-43-8, Methyl protococatechuate
3150-24-1, p-Nitrophenyl .beta.-D-galactoside 56128-66-6, Methyl
2,3,4-trihydroxybenzoate
RL: PRP (Properties)
(NMR of, effect of cyclodextrins on)
- IT 15155-16-5 24280-36-2 38567-80-5 61955-24-6 61955-25-7
78153-73-8 78153-74-9 78153-75-0 80065-26-5 132367-49-8
133055-38-6 133055-39-7 133055-40-0 133055-41-1
133055-42-2 133055-43-3 133055-44-4 133055-45-5 133055-46-6
133055-47-7 133055-48-8 133055-49-9 133055-50-2 133055-51-3
133055-52-4 133055-53-5 133055-54-6 133055-55-7 133055-56-8
133055-57-9 133055-58-0 133055-60-4 133055-61-5 133055-62-6
133055-63-7 133055-64-8 133055-65-9 133055-66-0 133055-67-1
133055-68-2 133055-69-3 133055-70-6 133055-71-7 133055-72-8
133055-73-9 133055-74-0 133055-75-1 133055-76-2 133055-77-3
133055-78-4 133055-79-5 133055-80-8 133055-81-9
133055-82-0 133055-83-1 133055-84-2 133055-85-3 133076-07-0
133161-09-8 133161-10-1 133161-11-2 133162-44-4 133267-31-9
133397-37-2
RL: PRP (Properties)

(assocn. const. of)
 IT 1333-74-0
 RL: RCT (Reactant)
 (hydrogen bond, of phenols and polyphenols with caffeine and cyclodextrins)

L92 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 1991:108936 HCAPLUS

DN 114:108936

TI Transdermal preparations containing **gallic acid** alkyl **esters** as absorption accelerators

IN Tsukahara, Hiroko; Azuma, Masato

PA Sekisui Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K009-70

ICS A61K047-14; A61L015-44; A61L015-58

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02202813	A2	19900810	JP 1989-23074	19890131
	JP 2638635	B2	19970806		
AB	Transdermal preps. contain gallic acid C1-18 alkyl esters as absorption accelerators. The esters are not irritating to the skin and absorbed readily through the skin. Isosorbide nitrate (I) 3, gallic acid Pr ester (II) 1, and AcOEt soln. contg. 20 wt.% 2-ethylhexyl acrylate-vinylpyrrolidone copolymer 100 wt. parts were mixed, coated on PET film, and dried to give tapes, which were applied to rabbits, resulting in max. plasma concn. of I 65.4 ng/mL 4 h later, vs. 26.8 ng/mL of the control prep. without II.				
ST	transdermal gallic acid alkyl ester				
IT	Drug bioavailability (of transdermal preps. contg. gallic acid alkyl esters as absorption accelerators)				
IT	Pharmaceutical dosage forms (tapes, contg. gallic acid alkyl esters as absorption accelerators)				
IT	Pharmaceutical dosage forms (transdermal, contg. gallic acid alkyl esters as absorption accelerators)				
IT	27234-90-8 RL: BIOL (Biological study) (pharmaceutical tapes contg. gallic acid alkyl ester and, with good bioavailability)				
IT	121-79-9, Gallic acid propyl ester 1034-01-1 1166-52-5, Gallic acid lauryl ester RL: BIOL (Biological study) (pharmaceutical transdermal preps. contg., as absorption accelerator)				

=> d his 193-

(FILE 'REGISTRY' ENTERED AT 10:24:44 ON 19 JAN 2002)

FILE 'HCAPLUS' ENTERED AT 10:24:56 ON 19 JAN 2002

L93 12 S L92 NOT L59
 SEL HIT RN

FILE 'REGISTRY' ENTERED AT 10:25:31 ON 19 JAN 2002

L94 24 S E8-E31
 L95 28 S L23,L29,L66

=> fil reg

FILE 'REGISTRY' ENTERED AT 10:27:22 ON 19 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3
DICTIONARY FILE UPDATES: 16 JAN 2002 HIGHEST RN 383858-27-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot 195

L95 ANSWER 1 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 291506-36-0 REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9E)-9-hexadecenyl ester (9CI) (CA INDEX
NAME)
FS STEREOSEARCH
MF C23 H36 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



*Hit compound
for reference*

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 2 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 291506-35-9 REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (6Z,9Z,12Z)-6,9,12-octadecatrienyl ester
(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H36 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 3 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 291506-34-8 REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9E,12E,15E)-9,12,15-octadecatrienyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H36 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 4 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 291506-33-7 REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9Z,12Z,15Z)-9,12,15-octadecatrienyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H36 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 5 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 291506-32-6 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (9E,12E)-9,12-octadecadienyl ester (9CI)
(CA INDEX NAME)


FS STEREOSEARCH

MF C25 H38 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:227794

L95 ANSWER 6 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 291506-31-5 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (9Z,12Z)-9,12-octadecadienyl ester (9CI)
(CA INDEX NAME)


FS STEREOSEARCH

MF C25 H38 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 7 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 291506-30-4 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (9Z)-9-hexadecenyl ester (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C23 H36 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 8 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 188819-08-1 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, cis-

OTHER NAMES:


CN (.+-.)-Epigallocatechin 3-gallate

CN (.+-.)-Epigallocatechol 3-gallate

FS STEREOSEARCH

DR 2596-50-1
 MF C22 H18 O11
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, TOXLIT, USPATFULL
 (*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:280620

REFERENCE 2: 129:197563

REFERENCE 3: 126:259162

L95 ANSWER 9 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 137766-94-0 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (2S,3S)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2S-cis)-

OTHER NAMES:

CN (+)-Epigallocatechin 3-gallate

CN (+)-Epigallocatechin gallate


FS STEREOSEARCH

MF C22 H18 O11

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMCATS, TOXCENTER, TOXLIT, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:280620
REFERENCE 2: 133:310854
REFERENCE 3: 131:314196
REFERENCE 4: 131:120607
REFERENCE 5: 126:220714
REFERENCE 6: 126:84603
REFERENCE 7: 116:734

L95 ANSWER 10 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 130405-40-2 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (2S,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2S-trans)-

OTHER NAMES:

CN (-)-Catechin gallate


FS STEREOSEARCH

MF C22 H18 O10

SR CA

LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

52 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

52 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:36568
 REFERENCE 2: 136:31686
 REFERENCE 3: 135:380367
 REFERENCE 4: 135:303146
 REFERENCE 5: 135:242062
 REFERENCE 6: 135:238128
 REFERENCE 7: 135:210069
 REFERENCE 8: 135:194757
 REFERENCE 9: 135:136564
 REFERENCE 10: 135:121339

L95 ANSWER 11 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 107965-88-8 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C22 H18 O11

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:303455

REFERENCE 2: 130:268510

REFERENCE 3: 106:171497

L95 ANSWER 12 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 36362-22-8 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (9E)-9-octadecenyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 9-octadecenyl ester, (E)-


FS STEREOSEARCH

MF C25 H40 O5

LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

REFERENCE 3: 76:139306

L95 ANSWER 13 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 25615-05-8 REGISTRY
 CN Benzoic acid, 3,4,5-trihydroxy-, (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2R-trans)-

CN Catechol, 3-gallate, (+)- (8CI)

CN Gallic acid, 3-ester with catechol, (+)- (8CI)

OTHER NAMES:

CN (+)-Catechin 3-gallate

CN (+)-Catechin 3-O-gallate

CN (+)-Catechin gallate


FS STEREOSEARCH

MF C22 H18 O10

CI COM

LC STN Files: AGRICOLA, BEILSTEIN*, CA, CAPLUS, TOXCENTER, TOXLIT
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

22 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

22 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:251475

REFERENCE 2: 135:190373

REFERENCE 3: 135:119578

REFERENCE 4: 134:55756

REFERENCE 5: 133:280725

REFERENCE 6: 133:48746

REFERENCE 7: 132:248555

REFERENCE 8: 131:271045

REFERENCE 9: 131:269465

REFERENCE 10: 128:99841

L95 ANSWER 14 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 20819-16-3 REGISTRY

CN **Benzoic acid, 3,4,5-trihydroxy-, (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, rel- (9CI) (CA INDEX NAME)**

OTHER CA INDEX NAMES:

CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, trans-**

CN Catechol, 3-gallate (7CI, 8CI)

OTHER NAMES:

CN Catechin 3-gallate

CN Catechin gallate

FS STEREOSEARCH


DR 10517-25-6

MF **C22 H18 O10**

LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, TOXCENTER, TOXLIT

(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

22 REFERENCES IN FILE CA (1967 TO DATE)

22 REFERENCES IN FILE CAPLUS (1967 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:47969

REFERENCE 2: 135:232986

REFERENCE 3: 135:194582

REFERENCE 4: 135:24380

REFERENCE 5: 135:14272

REFERENCE 6: 134:366018

REFERENCE 7: 134:83179

REFERENCE 8: 134:55705
REFERENCE 9: 133:263885
REFERENCE 10: 133:251502

L95 ANSWER 15 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 19065-20-4 REGISTRY

CN **Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, trans- (9CI) (CA INDEX NAME)**

OTHER CA INDEX NAMES:

CN Gallic acid, 3-ester with gallocatechol, (.+-.)- (8CI)

CN Gallocatechol, 3-gallate, (.+-.)- (8CI)


FS STEREOSEARCH

MF **C22 H18 O11**

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT

(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 71:12957

REFERENCE 2: 68:19544

L95 ANSWER 16 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 17431-25-3 REGISTRY

CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2S-cis)- (9CI) (CA INDEX NAME)**

OTHER CA INDEX NAMES:

CN Epicatechol, 3-gallate, (+)- (8CI)

CN Gallic acid, 3-ester with (+)-epicatechol (8CI)

OTHER NAMES:

CN (+)-Epicatechol 3-gallate


FS STEREOSEARCH

DR 20126-60-7

MF **C22 H18 O10**

LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)
 6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:220714

REFERENCE 2: 123:107779

REFERENCE 3: 116:734

REFERENCE 4: 83:75330

REFERENCE 5: 75:85219

REFERENCE 6: 67:52874

L95 ANSWER 17 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 15674-66-5 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (9Z)-9-octadecenyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN Gallic acid, (E)-9-octadecenyl ester (8CI)

FS STEREOSEARCH

MF C25 H40 O5

LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL
 (*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

REFERENCE 3: 66:3923

L95 ANSWER 18 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 13445-34-6 REGISTRY


CN Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C22 H18 O10

LC STN Files: BEILSTEIN*, CA, CAPLUS

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:267845

L95 ANSWER 19 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 5127-64-0 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (2R,3S)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-trans)-

CN Gallic acid, ester with gallocatechol


CN Gallocatechol gallate (6CI)

CN Gallocatechol, 3-gallate (7CI, 8CI)

OTHER NAMES:

CN (+)-Gallocatechol gallate
CN 3-O-Galloyl-(+)-gallocatechin
CN Gallocatechin 3-O-gallate
CN Gallocatechin gallate
FS STEREOSEARCH
DR 36291-30-2
MF **C22 H18 O11**
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA,
CAOLD, CAPLUS, DDFU, DRUGU, NAPRALERT, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

75 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
75 REFERENCES IN FILE CAPLUS (1967 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:48394
REFERENCE 2: 136:36568
REFERENCE 3: 136:541
REFERENCE 4: 136:509
REFERENCE 5: 135:285772
REFERENCE 6: 135:232986
REFERENCE 7: 135:216375
REFERENCE 8: 135:205163
REFERENCE 9: 135:194757
REFERENCE 10: 135:97422

RN 4233-96-9 REGISTRY
 CN Benzoic acid, 3,4,5-trihydroxy-, (2S,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2S-trans)-
 CN Gallic acid, ester with gallocatechol, (-)
 CN Gallocatechol, 3-gallate, (-)- (8CI)
 OTHER NAMES:
 CN (-)-Galocatechin 3-O-gallate
 CN (-)-Galocatechin gallate
 CN (-)-Galocatechol gallate
 CN NVP-XAA 225
 FS STEREOSEARCH
 MF C22 H18 O11
 LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, NAPRALERT, RTECS*, TOXCENTER, TOXLIT, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

113 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 113 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:31686
 REFERENCE 2: 135:380367
 REFERENCE 3: 135:303146
 REFERENCE 4: 135:242062
 REFERENCE 5: 135:238128
 REFERENCE 6: 135:235903
 REFERENCE 7: 135:207715

REFERENCE 8: 135:194582

REFERENCE 9: 135:166246

REFERENCE 10: 135:136564

L95 ANSWER 21 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 1257-08-5 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2R-cis)-

CN Epicatechol, 3-gallate, (-)- (8CI)

CN Epicatechol, gallate (6CI)

CN Gallic acid, 3-ester with epicatechol, (-)- (8CI)

OTHER NAMES:

CN (-)-epi-Catechin 3-O-gallate

CN (-)-Epicatechin 3-gallate

CN (-)-Epicatechin 3-O-gallate

CN (-)-Epicatechol gallate

CN 3-Galloyl-(-)-epicatechin

CN 3-O-Galloyl-(-)-epicatechin

CN 3-O-Galloylepicatechin

CN epi-Catechin 3-O-gallate

CN Epicatechin 3-O-gallate

CN Epicatechin gallate

CN Epicatechol 3-gallate

CN L-Epicatechin gallate

FS STEREOSEARCH


MF C22 H18 O10

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, IPA, NAPRALERT, RTECS*, TOXCENTER, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

720 REFERENCES IN FILE CA (1967 TO DATE)

4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

720 REFERENCES IN FILE CAPLUS (1967 TO DATE)

44 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:47969
 REFERENCE 2: 136:36568
 REFERENCE 3: 136:34579
 REFERENCE 4: 136:31686
 REFERENCE 5: 136:31626
 REFERENCE 6: 136:509
 REFERENCE 7: 136:177
 REFERENCE 8: 135:380367
 REFERENCE 9: 135:357329
 REFERENCE 10: 135:338720

L95 ANSWER 22 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 1166-52-5 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, dodecyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Gallic acid, dodecyl ester (6CI, 8CI)

OTHER NAMES:

CN Dodecyl 3,4,5-trihydroxybenzoate

CN Dodecyl gallate

CN Gallic acid lauryl ester

CN Lauryl 3,4,5-trihydroxybenzoate

CN Lauryl gallate

CN Nipagallin LA

CN Progallin LA

FS 3D CONCORD

DR 149030-04-6

MF C19 H30 O5


CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, NIOSHTIC, RTECS*, SPECINFO, TOXCENTER, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

456 REFERENCES IN FILE CA (1967 TO DATE)

4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

456 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 55 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:42534
 REFERENCE 2: 136:11208
 REFERENCE 3: 136:11151
 REFERENCE 4: 135:300632
 REFERENCE 5: 135:293977
 REFERENCE 6: 135:231498
 REFERENCE 7: 135:204919
 REFERENCE 8: 135:172948
 REFERENCE 9: 135:108911
 REFERENCE 10: 135:53458

L95 ANSWER 23 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 1034-01-1 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, octyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Gallic acid, octyl ester (6CI, 8CI)

OTHER NAMES:

CN n-Octyl gallate

CN Octyl 3,4,5-trihydroxybenzoate

CN Octyl gallate

CN Progallin O

CN Stabilizer GA 8

FS 3D CONCORD

MF C15 H22 O5


CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
 CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
 MSDS-OHS, NIOSHTIC, RTECS*, TOXCENTER, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

323 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

323 REFERENCES IN FILE CAPLUS (1967 TO DATE)

39 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:42534

REFERENCE 2: 136:11208
REFERENCE 3: 136:11151
REFERENCE 4: 135:293977
REFERENCE 5: 135:277718
REFERENCE 6: 135:204919
REFERENCE 7: 135:151922
REFERENCE 8: 135:137777
REFERENCE 9: 135:108911
REFERENCE 10: 135:41933

L95 ANSWER 24 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 989-51-5 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-

CN Epigallocatechol, 3-gallate (7CI)

CN Epigallocatechol, 3-gallate, (-)- (8CI)

CN Epigallocatechol, gallate (6CI)

CN Gallic acid, 3-ester with epigallocatechol, (-)- (8CI)

OTHER NAMES:

CN (-)-epi-Gallocatechin 3-O-gallate

CN (-)-Epigallocatechin 3-gallate

CN (-)-Epigallocatechin 3-O-gallate

CN (-)-Epigallocatechin gallate

CN (-)-Epigallocatechol gallate

CN 3-O-Galloyl-(-)-epigallocatechin

CN epi-Gallocatechin 3-O-gallate

CN Epigallocatechin 3-gallate

CN Epigallocatechin 3-O-gallate

CN Epigallocatechin gallate

CN L-Epigallocatechin gallate

CN NVP-XAA 723

FS STEREOSEARCH

DR 863-65-0


MF C22 H18 O11

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1410 REFERENCES IN FILE CA (1967 TO DATE)

18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1413 REFERENCES IN FILE CAPLUS (1967 TO DATE)

46 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:48387

REFERENCE 2: 136:48310

REFERENCE 3: 136:47969

REFERENCE 4: 136:42549

REFERENCE 5: 136:36568

REFERENCE 6: 136:34579

REFERENCE 7: 136:34578

REFERENCE 8: 136:32982

REFERENCE 9: 136:31686

REFERENCE 10: 136:31626

L95 ANSWER 25 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 863-03-6 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, cis-

CN Epicatechol, 3-gallate (7CI)

CN Gallic acid, 3-ester with epicatechol (8CI)

OTHER NAMES:

CN epi-Catechin 3-O-gallate

CN Epicatechin gallate

CN Epicatechol gallate

FS STEREOSEARCH


MF C22 H18 O10

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,

BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, DDFU, DRUGU, EMBASE,
MEDLINE, PROMT, TOXCENTER, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

291 REFERENCES IN FILE CA (1967 TO DATE)

4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

291 REFERENCES IN FILE CAPLUS (1967 TO DATE)

14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:42549
REFERENCE 2: 136:541
REFERENCE 3: 135:366381
REFERENCE 4: 135:359207
REFERENCE 5: 135:256206
REFERENCE 6: 135:216375
REFERENCE 7: 135:194940
REFERENCE 8: 135:140456
REFERENCE 9: 135:131661
REFERENCE 10: 135:117184

L95 ANSWER 26 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 149-91-7 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Gallic acid (7CI, 8CI)

OTHER NAMES:

CN 3,4,5-Trihydroxybenzoic acid

FS 3D CONCORD

MF C7 H6 O5

CI COM


LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,

CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*,
DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB,
IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA,
PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TOXLIT, TULSA, ULIDAT,
USAN, USPATFULL, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4734 REFERENCES IN FILE CA (1967 TO DATE)
371 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4748 REFERENCES IN FILE CAPLUS (1967 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:58907
REFERENCE 2: 136:58497
REFERENCE 3: 136:58496
REFERENCE 4: 136:52980
REFERENCE 5: 136:52508
REFERENCE 6: 136:47515
REFERENCE 7: 136:45692
REFERENCE 8: 136:42892
REFERENCE 9: 136:42890
REFERENCE 10: 136:40176

L95 ANSWER 27 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 121-79-9 REGISTRY

CN Benzoic acid, 3,4,5-trihydroxy-, propyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Gallic acid, propyl ester (6CI, 8CI)

OTHER NAMES:

CN n-Propyl 3,4,5-trihydroxybenzoate

CN n-Propyl gallate

CN Nipa 49

CN Nipagallin P

CN Nipanox S 1

CN PG

CN Progallin P

CN Propyl 3,4,5-trihydroxybenzoate

CN Propyl gallate

CN Tenox PG


FS 3D CONCORD

DR 56274-95-4

MF C10 H12 O5

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, GMELIN*,
HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS,
NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TOXLIT,
USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2041 REFERENCES IN FILE CA (1967 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2042 REFERENCES IN FILE CAPLUS (1967 TO DATE)
150 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:45424
REFERENCE 2: 136:42866
REFERENCE 3: 136:42790
REFERENCE 4: 136:42534
REFERENCE 5: 136:32996
REFERENCE 6: 136:32663
REFERENCE 7: 136:20568
REFERENCE 8: 136:19274
REFERENCE 9: 136:18006
REFERENCE 10: 136:11208


L95 ANSWER 28 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 99-24-1 REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, methyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gallic acid, methyl ester (6CI, 8CI)
OTHER NAMES:
CN 3,4,5-Trihydroxybenzoic acid methyl ester
CN Methyl 3,4,5-trihydroxybenzoate
CN Methyl gallate
FS 3D CONCORD
MF C8 H8 O5
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*,

IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA,
RTECS*, SPECINFO, TOXCENTER, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

615 REFERENCES IN FILE CA (1967 TO DATE)

22 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

616 REFERENCES IN FILE CAPLUS (1967 TO DATE)

34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE	1:	136:31380
REFERENCE	2:	135:295980
REFERENCE	3:	135:289857
REFERENCE	4:	135:258228
REFERENCE	5:	135:251475
REFERENCE	6:	135:242454
REFERENCE	7:	135:220669
REFERENCE	8:	135:207225
REFERENCE	9:	135:206895
REFERENCE	10:	135:205163